Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.
- Trial name
- DEVOTE (NCT01959529)
- Testing
- insulin degludec, insulin glargine
- Where
- 446 sites in United States, Algeria and 18 more
- Volunteers
- 7,637 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan
The purpose of this study was evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an Sulfonylurea taken QD or twice daily (BID) in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01318083
- Testing
- Alogliptin and glimepiride, Glimepiride
- Volunteers
- 312 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- NCT02505334
- Testing
- liraglutide
- Where
- 47 sites in Japan
- Volunteers
- 635 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
- Trial name
- NCT03235050
- Testing
- MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose
- Where
- 119 sites in United States, Bulgaria and 6 more
- Volunteers
- 834 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM), who have inadequate glycemic control on maximally or…
- Trial name
- NCT02025907
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 57 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
Albiglutide has been developed for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, as monotherapy, or in combination with existing therapies and has been approved by the United States (US)…
- Trial name
- NCT02750930
- Testing
- Albiglutide, Auto-injector
- Where
- 27 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Diabetes
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
- Trial name
- NCT00313313
- Testing
- Saxagliptin, Glyburide, Metformin
- Where
- 115 sites in United States, Argentina and 11 more
- Volunteers
- 768 people
- Sponsor
- AstraZeneca
Renal Impairment, Type 2 Diabetes Mellitus
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
This is a study to evaluate the effect of renal impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and in healthy participants with…
- Trial name
- NCT01948986
- Testing
- Ertugliflozin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)
A multiple dose study to assess the safety and pharmacokinetics of an investigational drug in patients with type 2 diabetes. The primary hypotheses of the study are that multiple daily MK-0941 in subjects with T2DM with or…
- Trial name
- NCT00511667
- Testing
- MK0941
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- NCT01081834
- Testing
- Canagliflozin, Sitagliptin
- Where
- 78 sites in United States, Austria and 16 more
- Volunteers
- 678 people
- Sponsor
- Janssen Research & Development, LLC
Obstructive Sleep Apnea, Sleep Apnea
Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism
Obstructive sleep apnea affects approximately 2-4% of middle-aged adults in the general population and is associated with several medical conditions including hypertension and coronary artery.
- Conditions
- Obstructive Sleep Apnea, Sleep Apnea, Sleep-disordered Breathing
- Trial name
- SOMNOS (NCT01503164)
- Testing
- Positive Pressure Therapy (PAP), LifeStyle Counseling
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Johns Hopkins University
Diabetes, Diabetes Mellitus, Type 2
Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess the implications of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01135992)
- Testing
- insulin degludec, insulin glargine
- Where
- 27 sites in United States
- Volunteers
- 143 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously…
- Trial name
- DUAL™ (NCT02100475)
- Testing
- insulin degludec/liraglutide, insulin aspart
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple ascending doses of PF-05231023.
- Trial name
- NCT01396187
- Testing
- PF-05231023
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pfizer
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.
- Trial name
- NCT00885378
- Testing
- Saxagliptin plus metformin IR
- Where
- 41 sites in United States, Germany and 2 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and North America. The aim of this clinical trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2…
- Trial name
- BEGIN™ (NCT01068678)
- Testing
- insulin degludec, insulin glargine
- Where
- 99 sites in United States, Canada and 6 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus…
- Trial name
- NCT02648217
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart
- Where
- 32 sites in Algeria, India and 4 more
- Volunteers
- 263 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and…
- Trial name
- NCT01525225
- Testing
- Metformin immediate release (IR), Saxagliptin, Metformin IR
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide
This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2…
- Trial name
- NCT00560417
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company